Blood cancers

Podcast: Minimal Residual Disease and why it’s important in ALL

Tuesday, 21 Apr 2020


For acute lymphoblastic leukaemia (ALL) the level and timing of response to therapy can be a powerful tool in guiding therapeutic choice. Minimal Residual Disease (MRD) is an approach that aims to detect residual tumour cells beyond the threshold of conventional evaluation methods.

In this podcast we’re joined on the phone by Professor Max Topp, head of haematology at the University Hospital of Wuerzburg, Germany, and Doctor Shaun Fleming, clinical haematologist at The Alfred in Melbourne to talk about what MRD actually means in clinical practice.

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic